Category: Peripheral Stents
Florida-based AxoGen touts an $18 million underwritten public offering of common stock, planning to expand commercial efforts for its peripheral nerve repair products.
Cook Medical launches a clinical study of its Zilver Vena stent, the 1st trial of its kind in the U.S. assessing an iliofemoral venous self-expanding stent.
Indiana medical device giant Cook Medical announced the launch of a new clinical study, the 1st of its kind evaluating the safety and effectiveness of its Zilver Vena venous self-expanding stent.
The VIVO study will enroll select adult patients experiencing limiting leg pain, leg swelling or skin discoloration or a healed or active lower leg ulcer, according to a Cook statement.
Johnson & Johnson's stenting arm, Cordis Corp. furthers its turn away from coronary stents toward the endovascular market with the acquisition of Flexible Stenting Solutions for an undisclosed amount.
Cordis Corp., the stent-making arm of healthcare colossus Johnson & Johnson (NYSE:JNJ), said it's acquired Flexible Stenting Solutions as part of turning its back on the coronary stents market in favor of the endovascular arena.
Medical device company Medtronic wins expanded European regulatory approval for its Complete SE self-expanding vascular stent.
Medtech titan Medtronic (NYSE:MDT) won new European regulatory consideration for its Complete SE vascular stent, gaining approval for use in the arteries that supply blood to the legs.
Medtronic won CE Mark approval in the European Union for use of the Complete SE self-expanding stent in the superficial femoral arteries and proximal popliteal arteries and announced international launch immediately.
Medical device maker Covidien wins CE Mark approval in the European Union for its EverFlex self-expanding stent system.
Medical device company Covidien (NYSE:COV) announced CE Mark approval in the European Union for its EverFlex self-expanding peripheral stent as well as for the accompanying Entrust delivery system.
Covidien plans to roll out the device in Western Europe next month, according to a press release.
Biotronik won FDA investigational device exemption and announced the 1st U.S. implant of its latest-generation Pulsar-18 self-expanding stent.
Cardiovascular medical device maker Biotronik touted FDA investigational device exemption for and 1st U.S. implantation of its Pulsar-18 self-expanding stent, the latest in the company's line of peripheral artery stents.
The FDA approval granted the Lake Oswego, Ore.-based company approval to add U.S. patients to its prospective, non-randomized study of the Pulsar-18 stent in the BioFlex-1 trial, which also includes centers in Europe and Canada, according to a press release.
Results from a 1-year follow-up of Medtronic's drug-eluting peripheral stent suggest that the implant may be an effective treatment for men with erectile dysfunction, but patient selection issues cut trial enrollment short.
MASSDEVICE ON CALL — Medical device industry giant Medtronic (NYSE:MDT) is temporarily giving up on its pursuit of erectile dysfunction-treating peripheral stenting, the company told reporters.
Disappointing enrollment experiences led Medtronic to suspend its Impasse trial, an angiography study of pelvic anatomy as associated with erectile dysfunction, which was intended to include 350 patients.